Conference MDAngle: ASN 2024 Glomerular Diseases

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.

The American Society of Nephrology (ASN) Kidney Week 2024 will take place in San Diego on October 24-27 and is expected to highlight the latest advancements in kidney research, patient care, and innovations in nephrology. Among the topics to be presented will be new therapeutic approaches for glomerular diseases such as C3 glomerulopathy, IgA nephropathy, and focal segmental glomerulosclerosis, including clinical trial data on targeted therapies, genetic testing for diagnosis and treatment, and insights into immune mechanisms and complement pathways in disease pathogenesis. The event will feature a mix of educational sessions, workshops, and presentations from global experts, providing an in-depth look at the evolving landscape of kidney health and disease management.

Nattawat Klomjit, MD

Assistant Professor of Medicine, Division of Nephrology and Hypertension and Department of Medicine, University of Minnesota; Staff Physician, Department of Medicine, Division of Nephrology and Hypertension, Minneapolis, Minnesota

“This is really exciting for us in the field of nephrology, because now we can treat the patients who are resistant to medications. Not only that, we’re also going to hear about updates in the field in regard to clinical care and clinical study. I also would like to see all the nephrologists all around the world come together, exchange ideas, and then collaborate to make sure that our field of nephrology is moving forward.”

Preconference Considerations

ASN 2024: Previewing Developments in Glomerular Diseases

In looking forward to ASN Kidney Week 2024, Dr Klomjit anticipates updates on some of the recent breakthroughs in treating glomerular diseases like IgA nephropathy, which now has three FDA-approved therapies. Dr Klomjit also gives attention to the potential of emerging treatments such as APRIL and BAFF inhibitors, CD38 blockades, C5 inhibitors, and CAR T-cell therapy, as well as the importance of global collaboration among nephrologists to advance the field.

Quick Clinical Takeaways

Coming soon: Dr Klomjit highlights new data and progress regarding glomerular diseases immediately following ASN.

How Will My Patients Benefit?

Coming soon: Reflections from Dr Klomjit on how new data on glomerular diseases from ASN 2024 will affect his patients.